About Vesicle-trafficking protein SEC22c
Vesicle-trafficking protein SEC22c (SEC22C) is a protein
from Homo sapiens identified by UniProt accession
Q9BRL7, 303 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Vesicle-trafficking protein SEC22c |
|---|
| UniProt accession | Q9BRL7 |
|---|
| Gene | SEC22C |
|---|
| Organism | Homo sapiens |
|---|
| Length | 303 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.15
- protein measurement · score 0.13
- fetal genotype effect measurement · score 0.13
- C-C motif chemokine 17 measurement · score 0.10
- monokine induced by gamma interferon measurement · score 0.10
- CCL19 measurement · score 0.10
- CCL17 measurement · score 0.10
- eosinophil count · score 0.06
- platelet component distribution width · score 0.02
- lung adenocarcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BRL7-F1 | alphafold | PREDICTED | 82.59 | — |
Amino-acid sequence (303 residues)
MSVIFFACVV RVRDGLPLSA STDFYHTQDF LEWRRRLKSL ALRLAQYPGR GSAEGCDFSI HFSSFGDVAC MAICSCQCPA AMAFCFLETL WWEFTASYDT TCIGLASRPY AFLEFDSIIQ KVKWHFNYVS SSQMECSLEK IQEELKLQPP AVLTLEDTDV ANGVMNGHTP MHLEPAPNFR MEPVTALGIL SLILNIMCAA LNLIRGVHLA EHSLQVAHEE IGNILAFLVP FVACIFQCYL YLFYSPARTM KVVLMLLFIC LGNMYLHGLR NLWQILFHIG VAFLSSYQIL TRQLQEKQSD CGV
Explore Vesicle-trafficking protein SEC22c with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets